Management ChangeJul 1, 2026, 08:01 AM
Annovis Bio Promotes Cheng Fang to Chief Scientific Officer
AI Summary
Annovis Bio, Inc. announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer. Dr. Fang, who previously served as Senior Vice President, Research and Development, will now lead scientific strategy and research operations for the company's Alzheimer's disease (AD) and Parkinson's disease (PD) programs. This promotion comes as Annovis advances its lead drug candidate, buntanetap, toward top-line data readout from its pivotal Phase 3 AD study and a subsequent New Drug Application (NDA) submission.
Key Highlights
- Cheng Fang, Ph.D., promoted to Chief Scientific Officer.
- Previously served as Senior Vice President, Research and Development.
- Will lead scientific strategy for Alzheimer's and Parkinson's programs.
- Promotion aligns with upcoming Phase 3 AD data readout.
- Company is preparing for New Drug Application (NDA) submission.
- Dr. Fang joined Annovis Bio in 2021.
- Buntanetap is the lead drug candidate for neurodegenerative diseases.
Price Impact
More from ANVS